Suppr超能文献

原发性肺泡蛋白沉积症的管理:一项多中心经验。

Management of primary pulmonary alveolar proteinosis: A multicentric experience.

作者信息

Marwah Vikas, Katoch C D S, Singh Sarvinder, Handa Ajay, Vardhan Vasu, Rajput A K, Barthwal M S, Bhattacharyya D, Rai S P

机构信息

Department of Pulmonary, Critical Care and Sleep Medicine, Army Institute of Cardio- Thoracic Sciences (AICTS), Pune, Maharashtra, India.

Department of Pulmonary, Critical Care and Sleep Medicine, Army Hospital (RR), Delhi Cantonment, Delhi, India.

出版信息

Lung India. 2020 Jul-Aug;37(4):304-309. doi: 10.4103/lungindia.lungindia_401_19.

Abstract

BACKGROUND

Pulmonary alveolar proteinosis (PAP) is a rare disease characterized by alveolar accumulation of surfactant material with reduced lung function and resulting hypoxemia. It is characterized by a variable clinical course, and whole lung lavage (WLL) is the standard treatment. Herein, we report our multicentric experience of management of primary PAP.

MATERIALS AND METHODS

This retrospective study included patients with PAP managed at various armed forces respiratory centers from 2009 to 2019. The diagnosis of primary PAP was based on histopathologic confirmation on transbronchial lung biopsy or open lung biopsy and absence of causes of secondary PAP. We analyzed the response to WLL in these patients as well as the safety of the procedure.

RESULTS

During the above-specified period, ten patients with a diagnosis of PAP were admitted to various armed forces respiratory centers. The median age of the patients was 34.5 years (range 23-59); there were nine males (90%). The mean duration (± standard deviation) of symptoms was 10.8 (±2.70) months. For management, WLL was done for eight patients with a median volume of 23.5 L (range 18-45) per patient. All the patients showed significant symptomatic response as well as improvement in physiological parameters with no major complications. The median follow-up of all patients was 18 (range 5-44) months.

CONCLUSIONS

WLL is a safe, effective therapy in an experienced setting in patients with PAP and provides long-lasting benefits.

摘要

背景

肺泡蛋白沉积症(PAP)是一种罕见疾病,其特征为肺泡表面活性物质积聚、肺功能降低并导致低氧血症。其临床病程多变,全肺灌洗(WLL)是标准治疗方法。在此,我们报告我们在原发性PAP治疗方面的多中心经验。

材料与方法

这项回顾性研究纳入了2009年至2019年在各武装部队呼吸中心接受治疗的PAP患者。原发性PAP的诊断基于经支气管肺活检或开胸肺活检的组织病理学确诊,且不存在继发性PAP的病因。我们分析了这些患者对WLL的反应以及该操作的安全性。

结果

在上述指定期间,10例诊断为PAP的患者入住各武装部队呼吸中心。患者的中位年龄为34.5岁(范围23 - 59岁);男性9例(90%)。症状的平均持续时间(±标准差)为10.8(±2.70)个月。为进行治疗,8例患者接受了WLL,每位患者的灌洗量中位数为23.5升(范围18 - 45升)。所有患者均表现出显著的症状改善以及生理参数的改善,且无重大并发症。所有患者的中位随访时间为18个月(范围5 - 44个月)。

结论

在有经验的医疗环境中,WLL对于PAP患者是一种安全、有效的治疗方法,并能带来持久益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9a0/7507921/7dbf5ad13c6d/LI-37-304-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验